Caladrius Biosciences to Participate at Upcoming May Conferences

Go Back
May 1, 2017

BASKING RIDGE, N.J., May 1, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development pipeline focused on immune modulation, announces today that experts from the Company’s PCT subsidiary will participate at the following upcoming May conferences:

International Society for Cell Therapy 2017 Annual Meeting

  • Date and Time: Thursday, May 4, 2017, 5:00 PM BST
  • Website:
  • Venue: ExCeL London Convention Centre, London, United Kingdom
  • Poster 1: Industrializing the Hospital: A Fully Closed, Automated Method for Processing Hematopoietic Stem Cell Transplants
  • Poster 2: The Future of T-Cell Therapy: Moving to Closed and Automated Manufacturing Using Novel Capture Particles
  • Co-Authors: David Smith, PhD, Senior Biomedical Engineer, PCT; Alex Klarer, Manufacturing Sciences and Technology Technician, PCT; Brian Hampson, Vice President, Global Manufacturing Sciences and Technology, PCT; Thomas Heathman, Business Leader, Technology Development, Manufacturing Development & GTP Services

American Society for Gene & Cell Therapy 2017 Annual Meeting

  • Date and Time: Wednesday, May 10, 2017 5:30 PM ET
  • Website:
  • Venue: Marriott Wardman Park Hotel, Washington, DC
  • Poster: Comparison of Rapid Sterility Testing Methods (BacT-Alerts Microbial Detection System versus MicroBio µ3D System) for Cell Therapy Product Release
  • Co-Authors: Silky Kamdar, PhD, Senior Scientist, Process Development, PCT; Brian Hampson, Vice President, Global Manufacturing Sciences and Technology, PCT; Bathakaly Jean-Charles, Process Development Associate II, PCT

World Advanced Therapies & Regenerative Medicine Congress 2017

Cell and Gene Exchange

  • Date and Time: Monday, May 22, 2017, 10:00 AM ET
  • Website:
  • Venue: Ronald Reagan Building, Washington, DC
  • Presentation: Introductory Remarks
  • Presenter: Robert Preti, PhD, President, PCT and Chairman, Alliance for Regenerative Medicine

Phacilitate SIG Automation

  • Date and Time: Tuesday, May 30, 2017, 3:50 PM GMT
  • Website:
  • Venue: Hopetoun House, Edinburgh, Scotland
  • Core Session: #7 Visualizing the Centralized Commercial Cell-Based Therapy Bioprocessing Facility of Tomorrow
  • Rapporteur: Brian Hampson, Vice President, Global Manufacturing Sciences and Technology, PCT

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company is investigating its lead product candidate, CLBS03, for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. The Company’s subsidiary, PCT, is a well-known development and manufacturing partner exclusively focused on the cell therapy industry and has served over 100 clients since 1999. For more information on Caladrius please visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 16, 2017, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.



Primary Logo

Source: Caladrius Biosciences, Inc.